Shopping Cart
- Remove All
Your shopping cart is currently empty
Epalrestat (ONO2235), an aldose reductase inhibitor, is well tolerated in Long-term therapy. It can effectually ameliorate the associated symptoms of diabetic neuropathy and delay the progression of the disease, particularly in patients with limited microangiopathy and good glycemic control.

| Pack Size | Price | Availability | Quantity |
|---|---|---|---|
| 10 mg | $30 | In Stock | |
| 25 mg | $44 | In Stock | |
| 50 mg | $61 | In Stock | |
| 100 mg | $87 | In Stock | |
| 200 mg | $127 | In Stock | |
| 500 mg | $209 | In Stock | |
| 1 mL x 10 mM (in DMSO) | $48 | In Stock |
| Description | Epalrestat (ONO2235), an aldose reductase inhibitor, is well tolerated in Long-term therapy. It can effectually ameliorate the associated symptoms of diabetic neuropathy and delay the progression of the disease, particularly in patients with limited microangiopathy and good glycemic control. |
| Synonyms | ONO2235 |
| Molecular Weight | 319.4 |
| Formula | C15H13NO3S2 |
| Cas No. | 82159-09-9 |
| Smiles | CC(=C/C1=CC=CC=C1)\C=C1/SC(=S)N(CC(O)=O)C1=O |
| Relative Density. | 1.43 g/cm3 |
| Color | Orange |
| Appearance | Solid |
| Storage | keep away from direct sunlight,keep away from moisture | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||
| Solubility Information | DMSO: 9 mg/mL (28.18 mM), Sonication is recommended. | |||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.